- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Low-dose colchicine may help prevent CV events in patients with type 2 diabetes and MI: COLCOT trial
Canada: Colchicine, 0.5 mg daily, leads to a large reduction in cardiovascular (CV) events among patients with type 2 diabetes (T2D) and a recent myocardial infarction (MI), new data from the COLCOT trial has shown.
The findings, published in Diabetes Care, offer further insight into the risks associated with and benefits of low-dose colchicine as a part of comprehensive secondary prevention approaches in patients with type 2 diabetes and a recent MI.
"In the prespecified analysis of the COLCOT trial, colchicine (0.5 mg daily) was linked with a 35% reduced risk of the primary composite endpoint of resuscitated cardiac arrest, cardiovascular death, stroke, myocardial infarction, and urgent hospitalization for angina needing revascularization in patients with type 2 diabetes and a recent MI," the researchers reported.
"Although the incidences of pneumonia and nausea were low, they were significantly greater in the colchicine arm than in the placebo arm."
In patients with coronary disease, the cardiovascular benefits of low-dose colchicine have been demonstrated. Jean-Claude Tardif, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada, and colleagues evaluated its effects in patients with type 2 diabetes from the COLchicine Cardiovascular Outcomes Trial (COLCOT).
COLCOT was a double-blinded, randomized trial of colchicine, 0.5 mg daily, versus placebo initiated within 30 days after a myocardial infarction. 959 patients with T2D were enrolled and monitored for a median of 22.6 months.
Based on the study, the following inferences were made:
- A primary endpoint event occurred in 8.7% of patients in the colchicine group and 13.1% in the placebo group (hazard ratio 0.65).
- Nausea was reported in 2.7% and 0.8% of the study groups, and pneumonia occurred in 2.4% and 0.4%.
"Among patients with type 2 diabetes and a recent myocardial infarction, colchicine, 0.5 mg daily, leads to a large reduction of cardiovascular events," the researchers wrote.
"These results support the conduct of the COLCOT-T2D trial in primary prevention," they concluded.
Reference:
François Roubille, Nadia Bouabdallaoui, Simon Kouz, David D. Waters, Rafael Diaz, Aldo P. Maggioni, Fausto J. Pinto, Jean C. Grégoire, Habib Gamra, Ghassan S. Kiwan, Colin Berry, José López-Sendón, Wolfgang Koenig, Laurent Delorme, Meyer Elbaz, Pierre Coste, Mylène Provencher, Zohar Bassevitch, Lucie Blondeau, Philippe L. L’Allier, Marie-Claude Guertin, Jean-Claude Tardif; Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care 2024; dc231825. https://doi.org/10.2337/dc23-1825
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751